MedTrace Logo

Guerbet Liver Fibrosis

NCT06703450 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-04-21

No results posted yet for this study

Summary

The goal of this study is to assess the value of liver dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and texture analysis post gadopiclenol for liver fibrosis staging, in comparison with MR elastography, T1 mapping, ultrasound elastography and blood tests in 50 initial patients with metabolic dysfunction-associated steatohepatitis (MASH).

Conditions

  • Metabolic Dysfunction-associated Steatotic Liver Disease

Sponsors & Collaborators

Principal Investigators

  • Sara Lewis, MD · Icahn School of Medicine at Mount Sinai

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-28
Primary Completion
2026-10-01
Completion
2026-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06703450 on ClinicalTrials.gov